We offer trading recommendations to enhance the recent expert consensus on Portage Biotech. Our recommendation engine uses a sophisticated algorithm to evaluate the company's growth potential based on available technical and fundamental data. Currently, Portage Biotech is not expected to issue dividends this year, as it aims to conserve or reinvest its funds. While investing in dividend-free stocks may seem risky, it can lead to significant capital gains. Investors can benefit from price increases over time, allowing them to sell their shares for a profit when the company performs well. Keep an eye on Portage Biotech for potential growth opportunities.
Key Takeaways
Portage Biotech (NASDAQ: PRTG) shows intriguing potential for growth, highlighted by a robust current ratio of 11.73X, indicating strong liquidity, despite facing a significant loss in free cash flow of
14.3M. Additionally, with a book value per share of
2.39 and a trailing PE of 0.42, the stock may present an attractive valuation opportunity for investors looking to capitalize on the biotechnology sector's volatility.
Typically, a company's
financial statements are the reports that show the
financial position of the company. There are three main documents that fall into the category of financial statements. These documents include Portage Biotech income statement, its balance sheet, and the statement of cash flows. Potential Portage Biotech investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Portage Biotech investors may use each financial statement separately, they are all related. The changes in Portage Biotech's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Portage Biotech's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our
technical analysis and
fundamental analysis pages.
The goal of Portage Biotech
fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of Portage Biotech performance into the future periods or doing a reasonable stock valuation. The intrinsic value of Portage Biotech shares is the value that is considered the true value of the share. If
the intrinsic value of Portage is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares Portage Biotech. Please read more on our
fundamental analysis page.
How effective is Portage Biotech in utilizing its assets?
Portage Biotech reports assets on its Balance Sheet. It represents the amount of Portage resources that either has an existing economic value or will provide some form of benefits in the future. By effectively utilizing its assets, Portage Biotech aims to generate revenue, control costs, drive operational efficiency, and enhance profitability. Optimizing asset utilization helps maximize shareholder value and maintain a competitive position in the Biotechnology space. To get a better handle on how balance sheet or income statements item affect Portage volatility, please check the breakdown of all its
fundamentals.
Are Portage Biotech Earnings Expected to grow?
The
future earnings power of Portage Biotech involves the interaction of many company-specific, industry, and economic forces. Earnings estimates embody investors' opinions of Portage Biotech factors such as sales growth, product demand, competitive industry environment, profit margins, and cost controls. Portage Biotech
stock prices adjust as these expectations change or are proven wrong. The main thing to remember is that equities with high expected earnings growth tend to underperform the market because it is usually difficult to meet the market's high expectations. Companies with low earnings expectations tend to do better than expected. Please use our latest analysis of Portage
expected earnings.
Portage Biotech Gross Profit
Portage Biotech Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Portage Biotech previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Portage Biotech Gross Profit growth over the last 10 years. Please check Portage Biotech's
gross profit and other
fundamental indicators for more details.
Detailed Perspective On Portage Biotech
Although in the United States, the Securities and Exchange Commission has enforced strong rules to prevent insiders from engaging in insider trading, finding insiders among active shareholders of Portage Biotech is not uncomon. There are few distinct groups of Portage Biotech stakehholders that the SEC considers insiders. Investors usually gain information through their work as corporate directors, officers, or employees. If these individuals share the information with a friend, family, or business partner and the person who receives the information exchanges stock in the company, he or shie is also an insider. Let's take a look at how the ownership of Portage is distributed among investors.
Ownership Allocation
The
market capitalization of Portage Biotech is $10.71 Million. Portage Biotech has significant amount of outstanding shares owned by
insiders. An
insider is usually defined as a CEO, other corporate executive, director, or
institutional investor who own at least 10% of the company's outstanding shares. Note, that even with negative
profits, if the true value of the company is larger than the current market value, you may still be able to generate positive returns on investment in this company.
| Retail Investors52.85% | Insiders36.39% | Institutions10.76% |
| Retail Investors | 52.85 |
| Insiders | 36.39 |
| Institutions | 10.76 |
Please be aware that individual investors typically purchase shares for their personal accounts and usually in smaller quantities compared to institutional investors. While they might influence Portage Biotech's decisions if they own a significant combined portion of its shares, such influence is relatively rare. Conversely, institutional investors - like mutual funds, pension funds, hedge funds, and other investment companies - often have a substantial sway over Portage Biotech's decisions due to their larger holdings.
| 2021 | 2022 | 2023 | 2024 (projected) |
Other Operating Expenses | 15.6M | 16.6M | 18.3M | 19.2M | Depreciation And Amortization | 15.6M | 1K | 54K | 51.3K |
Asset Utilization
One of the ways to look at asset utilization of Portage is to check how much profit was generated for every dollar of assets it reports. Portage Biotech holds a negative application of assets of -0.19 pct., losing $0.001942 for each dollar of assets held by the company. Inadequate asset utilization implies the company is being less effective with each dollar of assets it holds. Put it differently, asset utilization of Portage Biotech shows how discouraging it operates for each dollar spent on its assets.
| | | | | Intangible Assets87.7 M | Net Tangible Assets57.7 M |
| Non Current Assets Total | 79,799.05 | 0.0514 |
| Total Current Assets | 7.05 Million | 4.54 |
| Non Currrent Assets Other | 46,549.05 | 0.03 |
| Other Assets | 1.09 | 1.0E-6 |
| Other Current Assets | 2.76 Million | 1.78 |
| Intangible Assets | 87.73 Million | 56.46 |
| Net Tangible Assets | 57.71 Million | 37.14 |
In the world of investing, timing can be everything. Portage Biotech (NASDAQ: PRTG) has recently seen a surge in its stock price, prompting investors to consider its growth potential. Despite facing significant challenges, including a net income loss of 75.3 million and total operating expenses of 18.2 million, the company maintains a relatively low short ratio of 0.02X, indicating limited bearish sentiment among investors. With a market capitalization of approximately 7.3 million and a price-to-book ratio of 4.22X, Portage Biotech's fundamentals suggest that while the road ahead may be rocky, there could be potential for recovery and growth in the biotechnology sector. Investors should keep an eye on the company's ability to manage its liabilities, which total 4.5 million, as it navigates through its current financial landscape.
Breaking up Portage Biotech current price drop
Portage Biotech is experiencing a significant price drop, with a projected decline of 14.03%. This downturn has raised alarms among investors, as it indicates that traders may be betting against the stock, anticipating further difficulties. While this situation poses risks, it could also offer opportunities for investors looking to take advantage of potential rebounds or gain insights into the company's future.
The stock has shown considerable volatility, which can help investors time their moves in the market. By understanding these volatility trends, traders can assess Portage Biotech's risk compared to overall market fluctuations.
Increased volatility during bear markets can lead to sharp declines in the stock price, causing stress for investors and often prompting them to adjust their portfolios as prices fall.The recent drop of over 14 percent in Portage Biotech's stock price has raised eyebrows among investors. With a current valuation market value of
8.72, the stock appears to be trading below its naive expected forecast value of
11.06. Analysts have issued a consensus rating of "Hold," with the lowest estimated target price set at
9.1. This suggests that while the stock may not be a strong buy at the moment, there is potential for recovery. Investors should weigh the risks and consider the possible upside price of
35.93 against the backdrop of current market conditions before making any decisions..
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Ellen Johnson is a Member of Macroaxis Editorial Board. Ellen covers public companies in North America, focusing primarily on valuation and volatility. Six years of experience in predictive investment analytics and risk management.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Portage Biotech. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
[email protected]